Proximity-based therapeutics for novel disease treatments
Design signaling pathways for targeted cancer therapies; Create logic gates to control gene expression in rare diseases; Manipulate protein interactions in neurodegenerative disorders; Enable precise modulation of immune responses in autoimmune conditions; Develop therapies for metabolic disorders via spatial protein control
Founded in 2022; HQ in Seattle and Cambridge; Backed by Wilson Sonsini and Euclidean Capital; Employee count 11-50